EHA 2025 | The Young EHA Research Meeting: cellular therapies and more
Eleni Gavriilaki, MD, PhD, Aristotle University of Thessaloniki, Thessaloniki, Greece, comments on the Young EHA Research Meeting, which is part of the 30th Congress of the European Hematology Association (EHA) in Milan, Italy. Dr Gavriilaki highlights one of the four sessions, which will focus on cellular therapies, and encourages participation in the question-and-answer session. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We are very happy to have this year’s Young EHA Research Meeting on Saturday at the EHA. This research meeting is designed by the Young EHA Committee for the whole Young EHA community, but also for the whole research community. It’s part of the Congress and it addresses everyone. We have designed one of the four sessions to be focused on cellular therapies and especially pre-clinical development of that...
We are very happy to have this year’s Young EHA Research Meeting on Saturday at the EHA. This research meeting is designed by the Young EHA Committee for the whole Young EHA community, but also for the whole research community. It’s part of the Congress and it addresses everyone. We have designed one of the four sessions to be focused on cellular therapies and especially pre-clinical development of that. We’re very eager to hear a keynote lecture from Maria Themeli from Amsterdam. She is a well-known researcher in the field and actually very keen on new developments of cellular products. We know that these products have really saved the lives of many of our patients and even revolutionized outcomes for patients who would have had very bad results before the introduction of cellular therapies. But we are also very eager to improve the outcomes and potentially have new indications for our patients. One important thing in clinical practice right now is to introduce them earlier into the clinical algorithm and the lines of treatment, but I think we will have to learn more about new constructs and we will hear everything on this session that includes the keynote lecture and other additional two lectures from very important labs across Europe and international labs and from young researchers in this lab. We have also a Q&A discussion and we encourage everyone to participate.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
